Detalles de la búsqueda
1.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med
; 17(2): e1003038, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32092060
2.
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.
J Infect Dis
; 219(11): 1755-1765, 2019 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30615119
3.
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
J Virol
; 89(15): 7478-93, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25972551
4.
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
J Infect Dis
; 210(1): 99-110, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24403557
5.
Recent advances in humanized mice: accelerating the development of an HIV vaccine.
J Infect Dis
; 208 Suppl 2: S121-4, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24151317
6.
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
J Infect Dis
; 208(5): 818-29, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23840043
7.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV
; 11(5): e285-e299, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38692824
8.
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.
Pharmaceutics
; 16(5)2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38794258
9.
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Vaccine
; 41(42): 6309-6317, 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37679276
10.
Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
Vaccine
; 41(16): 2696-2706, 2023 04 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36935288
11.
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
J Clin Invest
; 133(4)2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36787249
12.
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens.
Sci Rep
; 10(1): 2093, 2020 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32034163
13.
Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
JCI Insight
; 5(13)2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32437332
14.
Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
Vaccine
; 36(4): 427-437, 2018 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29174315
15.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29898870
16.
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Clin Vaccine Immunol
; 23(6): 496-506, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27098021
17.
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
PLoS One
; 11(9): e0161753, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27583368
18.
Now that you want to take your HIV/AIDS vaccine/biological product research concept into the clinic: what are the "cGMP"?
Vaccine
; 33(15): 1757-66, 2015 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25698494
19.
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).
Open Forum Infect Dis
; 2(3): ofv082, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26199949
20.
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
Vaccine
; 29(10): 1948-58, 2011 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21216311